Under an exclusive marketing agreement, Neurobiological receives quarterly royalty payments on sales of Memantine by Merz and its marketing partners.
Paul Freiman, president and CEO of Neurobiological, said: “This royalty payment helps provide funding for our ongoing clinical program for Viprinex (ancrod) and contributes to our strong financial position.”